Harmony Biosciences Holdings Inc, a developer of biopharmaceuticals designed to identify, develop and commercialize treatment for narcolepsy and other central nervous system disorders, has filed Amendment No2 to Form S-1 Registration Statement on August 11, 2020 with the U.S Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $100 million by offering 4.7 million shares at a price range of $20 to $23. Assuming a successful IPO at the midpoint of the proposed range, the company expects a market capitalization of $1.4 billion.
The company’s product, WAKIX(pitolisant) is for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy, and it was approved by the U.S. Food and Drug Administration (FDA) in August 2019.
The Plymouth Meeting, Pennsylvania-based company was founded in 2017 and booked $26 million in net product revenue for the 12 months ended March 31, 2020. It plans to list on the Nasdaq under the symbol “HRMY.” Goldman Sachs, Jefferies, and Piper Sandler are underwriters of the IPO.
The company engages Latham & Watkins LLP as US Securities Counsel, and Deloitte & Touche LLP as Independent Auditor.
#ipo #nasdaq #deloitte #biotech #narcolepsy #centralnervoussystemdisorders
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
